Sanofi Loses Last-Ditch Bid To Upend Eloxatin Deal
A federal judge has deemed enforceable a deal that Sanofi-Aventis U.S. LLC reached with Sun Pharmaceutical Industries Ltd. ending a patent fight over generic versions of Sanofi's colon cancer drug Eloxatin,...To view the full article, register now.
Already a subscriber? Click here to view full article